Delta-Fly Pharma, Inc.
Notice of Large-Scale Exercise of the 12th Stock Acquisition Rights Issued Through Third-Party Allotment (Exercise Price Revision Clause)
Since the previous disclosure, the number of issued stock acquisition rights issued is 3,026,000 shares, with an exercise ratio of 30.26%; unexercised rights total 50,700 units (5,070,000 shares) remaining, a reduction from 80,960 units (8,096,000 shares) at the previous disclosure. As of September 9, with exercises on September 2 and the most recent exercise, 21,000 shares worth of stock acquisition rights have been exercised, representing a clearly over-exercise exceeding 10% of the total listed shares as of the payment date August 7.
Key Figures
- Delivered shares: 3,026,000 shares
- Unexercised stock acquisition rights: 50,700 units (5,070,000 shares)
- Exercise ratio: 30.26%
AI要約
Section Heading
This is a progress report on the large-scale exercise of the 12th stock acquisition rights issued through a third-party allotment. Of the total issued 100,000 units, the number of delivered shares to date is equivalent to 3,026,000 shares, with an exercise ratio of 30.26%, a high level. Unexercised shares have decreased to 5,070,000 shares, showing a notable impact on the total issued shares.
Section 2 Heading
Since the last disclosure, the exercise status includes 791,000 shares on September 2 and 2,100,000 shares on September 9, with a total of 21,000 shares actually exercised. This large exercise exceeds 10% of the listed shares as of the payment date August 7, and is described as not subject to restrictions under listing rules. Ongoing monitoring is required for potential dilution effects and shareholder value.
Delta-Fly Pharma, Inc.
Company overview · Stock price · Financial data · All IR
